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A 1-year, 8-month-old Rhodesian Ridgeback was presented with obtundation, ambulatory
tetraparesis, and myoclonus. Initial clinical findings included ionized hypercalcemia with an
apparent marked increase in parathyroid hormone, thrombocytopenia, and nonregenerative
anemia. Low numbers of circulating atypical cells were noted on blood film evaluation. Brain
magnetic resonance imaging identified an extra-axial contrast enhancing subtentorial lesion, and
cerebrospinal fluid (CSF) analysis documented a marked atypical lymphocytic pleocytosis. Flow
cytometry performed on the CSF demonstrated expression of only CD45, CD90, and MHC class
II, with Pax5 positivity on subsequent immunohistochemistry. The final diagnosis was of B-cell
lymphoblastic lymphoma or acute leukemia, given the distribution of disease and the presence
of significant bone marrow infiltration alongside an aggressive clinical course. The unusual
immunophenotype of the neoplastic cells and hypercalcemia presented antemortem diagnostic
challenges, highlighting the need for a multidisciplinary approach and caution in the interpreta-
tion of clinical abnormalities in cases with multiple comorbidities.
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1 | CASE REPORT
A 1-year, 8-month-old female neutered Rhodesian Ridgeback was pre-
sented to the Queen's Veterinary School Hospital for investigation of a
week-long history of lethargy, inappetence, and abnormal behavior,
consisting of vacant episodes with twitching of the head and forelimbs.
The owner reported weight loss of 3 kg over the preceding month. Per-
tinent medical history included an episode of weight loss and vomiting
7 months previously during which ionized hypercalcemia, hyperpho-
sphatemia, and increased symmetric dimethylarginine were documen-
ted by the primary care veterinarian. There was concurrent mild
thrombocytopenia, and “atypical” lymphocytes were reported (blood
film unavailable for review). These changes were attributed to presump-
tive ingestion of a toxic substance and treated symptomatically. No fur-
ther investigations were performed.
At presentation, the dog was lethargic and mildly dehydrated, and
on neurological examination, it was obtunded with ambulatory tetra-
paresis and proprioceptive ataxia. Postural reactions were reduced in
all limbs. Spontaneous irregular myoclonic jerks were observed affect-
ing the head and forelimbs both at rest and with movement, and there
was irregular muscle fasciculation in the hind limbs. Patella reflexes
were clonic bilaterally. There was a reproducible pain response on pal-
pation of the cervical and lumbar spine. No cranial nerve abnormalities
were detected.
Initial hematology documented marked thrombocytopenia
(30 × 103/μL); but despite repeated sampling, persistent platelet
Abbreviations: ALL, acute lymphoid leukemia; CNS, central nervous system;
CSF, cerebrospinal fluid; FLAIR, fluid attenuated inversion recovery; LBL, lym-
phoblastic lymphoma; PTH, parathyroid hormone; PTHrP, parathyroid
hormone-related peptide; T2WI, T2-weighted image.
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aggregation made reliable platelet enumeration impossible. Throm-
boelastography was within normal limits, as were prothrombin time
and activated partial thromboplastin time. There was borderline leuko-
penia (5.42 × 103/μL) caused by mild lymphopenia with a normal neu-
trophil count. Occasional intermediate- to large-sized atypical cells
with an irregularly round, paracentrally placed nucleus, ropy chromatin
(rarely with 1-2 irregularly round prominent nucleoli), and a small
amount of deeply basophilic cytoplasm were observed on the blood
film (Supporting Information Figure S1). These accounted for 6% of a
manual differential count performed on 200 cells (0.32 × 103/μL).
There was also moderate normocytic normochromic nonregenerative
anemia (PCV, 28%). On biochemistry, there was total and ionized
hypercalcemia (ionized calcium 7.2 mg/dL, reference interval
4.7-5.6 mg/dL). Parathyroid hormone (PTH) was markedly increased
(>1000 pg/mL) with undetectable parathyroid hormone-related pep-
tide (PTHrP). As hyperparathyroidism was considered clinically
unlikely, further analysis was performed by the reference laboratory
including serial sample dilution. This yielded a nonlinear result, sugges-
tive of assay interference. There was concurrent mild hyperphospha-
temia (6.1 mg/dL, reference interval 2.5-5.4 mg/dL) and increased
C-reactive protein (37 mg/L, reference interval 0-8.2 mg/L) consistent
with a systemic inflammatory response (full hematology and biochem-
istry results in Supporting Information Table S1). Infectious disease
screening was negative (serology using an indirect fluorescent anti-
body test for Toxoplasma gondii and Neospora caninum; SNAP 4Dx
Plus and Angio Detect; IDEXX Laboratories Inc, Westbrook, Maine).
Urinalysis documented isosthenuria (specific gravity 1.010), attributed
to the results of hypercalcemia and prior fluid treatment.
Abnormalities were not detected on radiographs of the thorax
and lumbar spine; however, on abdominal ultrasound, the spleen was
enlarged with heterogeneous echogenicity, the liver appeared hetero-
geneous, and there was a mild reduction in renal corticomedullary def-
inition bilaterally. The parathyroid glands were prominent on
ultrasound but within normal size limits (0.21 cm diameter). Electro-
myography under general anesthesia did not identify any abnormali-
ties. Magnetic resonance imaging of the brain and cranial cervical
spine (Esaote, VetMR 0.3Ts.p.a; Genoa, Italy) revealed a right-sided
extra-axial triangular-shaped plaque-like area of contrast enhance-
ment located just ventral to the tentorium cerebelli (Figure 1A). This
lesion was not visible on any of the precontrast T1-weighted image
(WI), T2WI, short tau inversion recovery, or fluid attenuated inversion
recovery (FLAIR) sequences and extended the entire height of the
tentorium cerebelli, with no mass effect on adjacent tissues. A menin-
geal tail was seen extending from the lesion dorsally and ventrally,
and a fainter less-defined area of contrast uptake was seen along the
ventral aspect of the cerebellum on the left side. Both retropharyngeal
lymph nodes were prominent, with the left side slightly larger and
more FLAIR hyperintense than the right side. Ventrally and caudally in
the left retropharyngeal lymph node there was an ill-defined area of
contrast uptake, corresponding to a T2WI hyperintensity on the pre-
contrast sequences (Supporting Information Figure S2).
Cisternal cerebrospinal fluid (CSF) analysis documented a marked
pleocytosis (1415 cells/μL) with a predominance of intermediate- to
large-sized atypical round cells, considered of likely lymphoid origin
and with an appearance similar to those observed in the blood
(Figure 2). Cerebrospinal fluid microprotein was also increased (0.9 g/L).
Multicolor flow cytometry was performed using established laboratory
protocols (BD Accuri C6 cytometer and software; BD Biosciences, San
Jose, California, antibodies listed in Supporting Information Table S2),
with data acquired on 10 000 gated events. A population of
intermediate- to large-sized cells were gated according to their light
scatter properties (Figure 3A). Positivity was determined by comparison
to isotype controls, and a result was considered positive when the
marker was expressed by more than 20% of gated cells, with the excep-
tion of CD34, where a cutoff value of 5% was used. The cells in the
gated region displayed strong expression of the panleukocyte marker
CD45, as well as CD90 and major histocompatability complex (MHC)
class II. All other markers tested were negative, including the additional
pan-leukocyte marker CD18, the T-cell markers CD3, CD4, CD5, CD8,
and CD3-12, the B-cell markers CD21 and CD79a, and the myeloid
FIGURE 1 A, T1-weighted post-gadolinium transverse magnetic
resonance imaging view of the brain at the level of the cerebellum
demonstrating a wedge-shaped area of contrast uptake ventral to the
right tentorium cerebelli (red arrow). B, Photomicrograph of the
cerebellum. The cerebellar leptomeninges are markedly expanded by
sheets of neoplastic round cells (black arrows). Hematoxylin and
eosin. Scale bar = 100 μm
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markers CD14 and myeloperoxidase. CD34, the marker most frequently
used to identify blasts in acute leukemia (ALL), was also negative. A pre-
liminary diagnosis of poorly differentiated hematopoietic neoplasia with
a likely lymphoid origin was made. Flow cytometric evaluation of the
peripheral blood suggested the presence of a small population of cells
with similar scatter properties and immunophenotype to those in the
CSF (approximately 4.6% of events when cellular debris was excluded,
as shown in Figure 3B,C), believed likely to correspond to those seen on
the blood film.
Initial symptomatic treatment included levetiracetam (20 mg/kg
q8h) and prednisolone (approximately 1 mg/kg q24h). The dog
remained stable for 2 days; however, because of the poor prognosis
associated with central nervous system (CNS) lymphoproliferative neo-
plasia, the owner elected for euthanasia, and a full postmortem exami-
nation was requested. Gross findings supported the imaging findings
and included a moderate loss of the folia pattern in the cerebellum and
the presence of multifocal areas of soft, homogenous tan to pale pink
FIGURE 3 A-C, Plots displaying the results of flow cytometric analysis
of the cerebrospinal fluid (CSF) and the blood. A, Representative plot
displaying scatter properties of the cells in the CSF, with forward scatter
corresponding to size and side scatter to complexity. The red dotted line
surrounds the events gated for further analysis, believed to correspond
to the cells seen on cytology. B, Cell populations in the blood illustrated
using color back-gating by expression of CD18 (panleukocyte marker)
and CD5 (T-cell marker). The events (cells) in the pink box are double
negative for CD18 and CD5, corresponding to the circulating atypical
cells (4.6%). The events in the blue box are double positive for CD18 and
CD5, corresponding to a residual population of circulating T-cells
(10.4%). The events in the orange box are positive for CD18 but
negative for CD5, corresponding predominantly to the normal circulating
neutrophils and monocytes. C, Representative plot displaying the scatter
properties of the events (cells) in the blood defined in (B). Events with a
low forward scatter (debris) have been excluded. Note that the cells
shown in pink (CD18/CD5 double negative atypical cells) have similar
scatter properties to those in the CSF shown in (A)
FIGURE 2 A and B, Cytospin preparation of cerebrospinal fluid
stained with Wright's Giemsa. A, The preparation is highly cellular,
and the predominant cells are a population of intermediate- to large-
sized atypical round cells (×200 magnification, scale bar = 50 μm). B,
The atypical cells (example indicated by red arrow) are on average
1-1.5 times the neutrophil diameter (nondegenerate neutrophil
indicated by the yellow arrow for size comparison), with an irregularly
round to indented nucleus and moderate amount of basophilic
cytoplasm. Chromatin is ropy with 1-3 prominent nucleoli. Frequent
mitotic figures are present (black arrows) (×500 magnification, scale
bar = 20 μm)
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tissue overlying the spinal cord. Cytology of the bone marrow was
hypercellular with significant infiltration (approximately 56%) by atypi-
cal cells with a similar morphology to those in the CSF and blood
(Figure 4). Special staining with alkaline phosphatase was negative.
There was concurrent erythroid hypoplasia, although megakaryocyte
numbers appeared adequate with an increased proportion of immature
megakaryocytes. These findings were confirmed on core biopsy.
Major histopathological findings included the presence of multi-
focal to coalescing infiltrative sheets and clusters of intermediate-
sized neoplastic round cells in the cerebellum, spinal cord, and
nerve roots (Figures 1B and 5). On immunohistochemistry, the cells
exhibited strongly positive nuclear staining for Pax5, indicating a
B-cell origin. Other lymphoid markers including CD3, CD79a, and
CD20 were negative. The normal architecture of the retropharyn-
geal lymph nodes was effaced by sheets of similar neoplastic cells,
which exhibited a mitotic rate of 87 per 10 high-power fields (per
2.37 mm2). Additional morphological diagnoses included moderate
chronic interstitial nephritis and mild-to-moderate multifocal infarc-
tion of the kidneys. The parathyroid glands were microscopically
within normal limits. The final histopathological diagnosis was of
intermediate-sized B-cell lymphoproliferative neoplasia affecting
the spinal cord, retropharyngeal lymph nodes, and bone marrow. In
combination with the antemortem findings, the overall picture was
considered suggestive of B-cell lymphoblastic lymphoma (LBL)
or ALL.
FIGURE 4 A and B, Cytology of the hypercellular bone marrow,
demonstrating a population of cells similar to those observed in the
cerebrospinal fluid. These accounted for 56% of a 500-cell differential
count. May-Grünwald Giemsa. A, Magnification ×200, scale
bar = 50 μm. B, Magnification ×500, scale bar = 20 μm. The black
arrows indicate examples of the neoplastic cells, whereas the red arrow
indicates a rare erythroid lineage cell. There are also low numbers of
band and mature neutrophils and occasional small lymphocytes
FIGURE 5 A-C, Photomicrographs of histopathological sections of
the spinal cord. A, Multifocal to coalescing infiltrates of neoplastic
round cells expand the leptomeninges and underlying white matter.
Hematoxylin and eosin. Scale bar = 100 μm. B, Higher magnification
of the spinal white matter showing a perivascular infiltrate of
neoplastic cells. Scale bar = 100 μm. C, The majority of the neoplastic
cells exhibit intense nuclear staining for Pax5 with hematoxylin
counterstain. Scale bar = 100 μm
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2 | DISCUSSION
This case of myoclonus in a dog was associated with poorly differentiated
lymphoproliferative neoplasia with presumed CNS invasion. The findings
on neurological examination correlated well with the multifocal distribu-
tion of lesions confirmed at postmortem; however, the unusual immuno-
phenotype of the neoplastic cells identified using flow cytometry made
definitive antemortem diagnosis challenging. The dog's history and hyper-
calcemia presented additional diagnostic and interpretive challenges, as
did the presence of a presumed interfering substance in the PTH assay.
Myoclonus is the presence of sudden, shock-like involuntary move-
ments and is an infrequent presentation in dogs with neurological disease.
It can be classified according to phenotype, etiology, pathophysiology,
neuroanatomical localization, pharmacological response, and moment of
occurrence.1 In veterinary medicine, classification as epileptic and nonepi-
leptic myoclonus has been proposed based on the presence or absence of
generalized tonic-clonic seizures. In this case, the myoclonic movements
were noninducible sporadic muscular contractions (positive myoclonus) of
the head and cervical region. The dog had concurrent obtundation and
episodic vacancies that could suggest the presence of seizure activity.
However, in the absence of generalized tonic-clonic seizures and electro-
encephalographic evidence of abnormal cerebrocortical activity, epileptic
myoclonus is difficult to diagnose. Instead, an etiological classification of
nonepileptic or symptomatic myoclonusmight be preferable in this case.
The most frequent reports of symptomatic myoclonus in dogs involve
canine distemper virus infection or more rarely lead toxicosis or other
inflammatory CNS disease.2 The pathogenesis of myoclonus in these con-
ditions is incompletely understood, although it is believed to be the result
of focal lesions causing pathological changes to the function of lowermotor
neurons of the spinal cord and cranial nerves. There are several reports of
humans with both intracranial and extracranial neoplasms presenting with
myoclonus either as part of paraneoplastic syndromes, as occurs in opso-
clonus myoclonus syndrome,3 or because of a direct insult on the nervous
tissue. In most cases, these conditions are believed to have an immune-
mediated basis involving onconeuronal antibodies, even in caseswhere the
location of lesions within the CNS could explain the signs.4Histopathology
in this case demonstrated infiltrative neoplastic lymphocytes distributed
multifocally in the CNS, and thus, a direct disturbance of the cortical or spi-
nal neuronal function can be hypothesized as the cause of myoclonus.
However, as suggested in the literature, an indirect immune-mediated
cause might be more plausible, either involving onconeuronal antibodies
(which can be measured in human CSF) or immune dysregulation as can
occur in neoplasms of the immune system.5–7
Lymphoid neoplasia with CNS involvement has been widely
reported in dogs, most often as part of a multicentric process and
rarely as a primary CNS neoplasm. In dogs, neurological signs occur
most often during relapse of previously diagnosed lymphoma,8
although in humans, CNS involvement is a recognized risk factor in
many lymphoproliferative diseases, especially LBL/ALL. A single case
report has described B-ALL with meningeal metastasis in a dog.9 The
findings in our case are most consistent with CNS metastasis (second-
ary involvement), and the distribution of lesions on histopathology
was similar to those described in a recent paper documenting a single
case of B-LBL with a perivascular and meningeal pattern.10
Immunophenotyping of lymphoproliferative neoplasms using flow
cytometry is well established in human medicine and increasingly uti-
lized in veterinary medicine. In this case, the flow cytometric findings
were unusual in that the neoplastic cells lacked expression of all
mature B- and T-cell markers. The expression of CD45 and MHC class
II was considered nonspecific as both may be expressed by a wide
variety of leukocytes. CD90 has traditionally been accepted as a
marker of T-cells and monocytes in dogs,11 and as such, a T-cell origin
of the neoplastic cells was considered most likely antemortem. How-
ever, on immunohistochemistry, the expression of Pax5 (a highly spe-
cific B-cell marker in humans and dogs) was consistent with a B-cell
neoplasm.12,13 In human medicine, CD90 is considered more broadly
as a marker of stem cells,14 and some authors in the veterinary litera-
ture also interpret it as such15 although specific evidence to demon-
strate this is lacking. The expression of CD90 by a clinically aggressive
B-cell neoplasm in this case lends support to this broader approach,
and further investigations into the expression of CD90 in canine lym-
phoproliferative neoplasia could be beneficial. This may be of interest
when expression of CD34 (stem cell marker associated with ALL) is
absent, as can occur in some cases of clinically diagnosed ALL.15
The definitive classification of the neoplasm in this case is some-
what controversial given the difficulty in differentiating between poorly
differentiated stage V lymphoma (eg, LBL) and ALL. In humans, the
degree of bone marrow involvement is critical in making this distinction,
with a cutoff of greater than 25% infiltration being consistent with
ALL.16 Similar definitions have been applied in the veterinary
literature,17 and according to these, the diagnosis in this case should be
of B-ALL (given the 56% of neoplastic cells documented in the bone
marrow). The clinical course and distribution of disease should also be
considered, with lymphomas typically having more significant involve-
ment of lymphoid tissues outside the bone marrow (not observed in
this case). However, in the absence of confirmatory cytogenetic testing
(routinely used in human medicine) and given the late stage at which
dogs with lymphoma frequently present, it could be argued that such a
cutoff is inappropriate and could result in overdiagnosis of ALL.
Although the bone marrow involvement generally confers a worse
prognosis in dogs with lymphoma,18 the well-established poor progno-
sis of ALL in dogs might be more likely to result in euthanasia when
such a diagnosis is made. In cases such as ours with CNS involvement,
this is arguably less of a concern given the poor prognosis this confers
alone. However, with further advances in veterinary diagnostics and
treatment, this could become an important discussion point.
Platelet aggregation (hyperreactivity) is a common finding in dogs
with lymphoma and is believed to play a role in tumor metastasis and
confer an increased risk of disseminated intravascular coagulation.19
Thrombocytopenia is a common finding in dogs with lymphoid neopla-
sia and is frequently multifactorial.20 Given the presence of adequate
megakaryocytes on bone marrow evaluation in this dog, the apparent
thrombocytopenia was believed most likely primarily the result of
increased platelet consumption or sequestration.
The cause of hypercalcemia in this case remains unexplained, with
differentials including vitamin D secretion by neoplastic cells and
osteolysis (although no specific evidence of this was identified).21
Repeated samples were measured, making laboratory error unlikely.
PTHrP was undetectable, excluding a classical hypercalcemia of
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malignancy, and other differentials such as hypoadrenocorticism and
renal disease were considered very unlikely in the absence of other
suggestive findings. Ionized calcium (and phosphate) is expected to be
above typical adult reference values in growing large breed dogs;22
however, the degree of increase in PTH and age of this dog are likely
incompatible. The marked increase in PTH documented during initial
testing was considered inconsistent with the other clinical findings
and signalment in this case. As such, further investigations were per-
formed by the reference laboratory, including the addition of further
(Ethylenediaminetetraacetic acid, EDTA) to the sample and the testing
of serial dilutions. The lack of linearity in these dilutions suggested the
presence of an assay interferent. A common cause of interference in
human immunoassays is the presence of heterophilic antibodies,23
and although the nature of the substance in this case remains
unknown, this could provide an explanation given the known occur-
rence of antibody production and secondary immune-mediated dis-
ease in lymphoma. These findings highlight the need for caution in the
interpretation of immunoassay results in dogs with significant under-
lying disease and inconsistent clinical signs.
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